Guangzhou Kingmed Diagnostics Group Co., Ltd. (603882.SS)
CNY 31.24
(-1.26%)
CNY 31.24
(-1.26%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -1.87 Billion CNY | 20.41% |
| 2022 | -2.36 Billion CNY | -16.2% |
| 2021 | -2.03 Billion CNY | -73.06% |
| 2020 | -1.17 Billion CNY | -244.95% |
| 2019 | -340.27 Million CNY | -253.86% |
| 2018 | -96.15 Million CNY | -32.48% |
| 2017 | -72.58 Million CNY | -141.08% |
| 2016 | 176.66 Million CNY | 3869.4% |
| 2015 | 4.45 Million CNY | -96.9% |
| 2014 | 143.75 Million CNY | 4990.19% |
| 2013 | 2.82 Million CNY | 109.45% |
| 2012 | -29.88 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | -1.36 Billion CNY | -25.02% |
| 2024 Q1 | -1.5 Billion CNY | 19.87% |
| 2024 Q2 | -1.09 Billion CNY | 27.49% |
| 2023 Q4 | -1.87 Billion CNY | -26.09% |
| 2023 FY | -1.87 Billion CNY | 20.41% |
| 2023 Q1 | -2.38 Billion CNY | -0.86% |
| 2023 Q2 | -1.52 Billion CNY | 35.82% |
| 2023 Q3 | -1.48 Billion CNY | 2.48% |
| 2022 Q3 | -2.14 Billion CNY | 13.53% |
| 2022 Q2 | -2.48 Billion CNY | -32.7% |
| 2022 Q1 | -1.87 Billion CNY | 7.84% |
| 2022 FY | -2.36 Billion CNY | -16.2% |
| 2022 Q4 | -2.36 Billion CNY | -9.88% |
| 2021 Q1 | -1.03 Billion CNY | 11.72% |
| 2021 Q3 | -1.22 Billion CNY | -9.31% |
| 2021 Q4 | -2.03 Billion CNY | -65.44% |
| 2021 FY | -2.03 Billion CNY | -73.06% |
| 2021 Q2 | -1.12 Billion CNY | -8.4% |
| 2020 Q4 | -1.17 Billion CNY | -48.38% |
| 2020 FY | -1.17 Billion CNY | -244.95% |
| 2020 Q1 | -97.44 Million CNY | 71.36% |
| 2020 Q2 | -234.9 Million CNY | -141.07% |
| 2020 Q3 | -791.05 Million CNY | -236.76% |
| 2019 FY | -340.27 Million CNY | -253.86% |
| 2019 Q4 | -340.27 Million CNY | -108.88% |
| 2019 Q3 | -162.9 Million CNY | -323.73% |
| 2019 Q2 | -38.44 Million CNY | -318.39% |
| 2019 Q1 | -9.18 Million CNY | 90.44% |
| 2018 Q1 | 49.19 Million CNY | 167.78% |
| 2018 Q2 | 75.27 Million CNY | 53.01% |
| 2018 FY | -96.15 Million CNY | -32.48% |
| 2018 Q3 | 71.13 Million CNY | -5.5% |
| 2018 Q4 | -96.15 Million CNY | -235.19% |
| 2017 Q3 | -90.81 Million CNY | -126.82% |
| 2017 Q1 | 529.76 Million CNY | 199.87% |
| 2017 FY | -72.58 Million CNY | -141.08% |
| 2017 Q2 | 338.56 Million CNY | -36.09% |
| 2017 Q4 | -72.58 Million CNY | 20.08% |
| 2016 Q4 | 176.66 Million CNY | 0.0% |
| 2016 FY | 176.66 Million CNY | 3869.4% |
| 2015 Q3 | -72.81 Million CNY | 0.0% |
| 2015 FY | 4.45 Million CNY | -96.9% |
| 2015 Q4 | 4.45 Million CNY | 106.11% |
| 2014 FY | 143.75 Million CNY | 4990.19% |
| 2013 FY | 2.82 Million CNY | 109.45% |
| 2012 FY | -29.88 Million CNY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Shanghai Runda Medical Technology Co., Ltd. | 5.96 Billion CNY | 131.49% |
| Joinn Laboratories(China)Co.,Ltd. | -2.77 Billion CNY | 32.351% |
| WuXi AppTec Co., Ltd. | -4.24 Billion CNY | 55.762% |
| Autobio Diagnostics Co., Ltd. | -448.29 Million CNY | -319.075% |
| Thalys Medical Technology Group Inc. | 772.55 Million CNY | 343.178% |
| Chemclin Diagnostics Co., Ltd. | -214.05 Million CNY | -777.664% |